Deep Track Capital LP Takes $38.92 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Deep Track Capital LP acquired a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,540,132 shares of the biopharmaceutical company's stock, valued at approximately $38,919,000. Celldex Therapeutics accounts for approximately 1.4% of Deep Track Capital LP's investment portfolio, making the stock its 23rd biggest holding. Deep Track Capital LP owned about 2.32% of Celldex Therapeutics at the end of the most recent quarter.

Several other large investors also recently modified their holdings of CLDX. EverSource Wealth Advisors LLC grew its holdings in shares of Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares during the last quarter. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics in the fourth quarter worth $81,000. KBC Group NV boosted its position in Celldex Therapeutics by 79.1% during the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,647 shares during the last quarter. AlphaQuest LLC lifted its stake in Celldex Therapeutics by 171.0% in the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company's stock valued at $108,000 after acquiring an additional 2,705 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in Celldex Therapeutics during the fourth quarter worth approximately $121,000.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CLDX shares. Morgan Stanley dropped their target price on shares of Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a report on Friday. The Goldman Sachs Group cut their target price on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a research report on Friday. Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. HC Wainwright reaffirmed a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday, May 6th. Finally, UBS Group decreased their price objective on Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $53.90.

Celldex Therapeutics Stock Performance

Shares of Celldex Therapeutics stock traded up $1.67 during trading hours on Monday, hitting $20.00. The company's stock had a trading volume of 299,421 shares, compared to its average volume of 887,625. The firm has a fifty day moving average of $18.99 and a 200-day moving average of $22.80. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -7.77 and a beta of 1.39. Celldex Therapeutics, Inc. has a twelve month low of $14.40 and a twelve month high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. On average, sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.